Investors Buy Large Volume of Put Options on Maravai LifeSciences (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) was the target of some unusual options trading activity on Wednesday. Traders acquired 1,002 put options on the company. This represents an increase of approximately 1,791% compared to the average volume of 53 put options.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on MRVI shares. Morgan Stanley lowered their target price on shares of Maravai LifeSciences from $7.00 to $5.00 and set an "equal weight" rating for the company in a research note on Tuesday, March 25th. Stifel Nicolaus set a $5.00 target price on shares of Maravai LifeSciences in a research note on Friday, March 21st. Robert W. Baird lowered their target price on shares of Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. UBS Group lowered their target price on shares of Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating for the company in a research note on Friday, March 21st. Finally, Baird R W lowered shares of Maravai LifeSciences from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $6.64.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of MRVI. Performa Ltd US LLC boosted its holdings in shares of Maravai LifeSciences by 614.3% in the 4th quarter. Performa Ltd US LLC now owns 5,000 shares of the company's stock valued at $27,000 after purchasing an additional 4,300 shares during the last quarter. McAdam LLC acquired a new position in shares of Maravai LifeSciences during the 1st quarter valued at $31,000. EntryPoint Capital LLC acquired a new position in shares of Maravai LifeSciences during the 1st quarter valued at $32,000. Teacher Retirement System of Texas purchased a new stake in Maravai LifeSciences during the 1st quarter worth $37,000. Finally, Aigen Investment Management LP purchased a new stake in Maravai LifeSciences during the 1st quarter worth $37,000. 50.25% of the stock is owned by hedge funds and other institutional investors.

Maravai LifeSciences Trading Down 5.8%

Shares of NASDAQ:MRVI traded down $0.13 during midday trading on Friday, reaching $2.13. 992,677 shares of the company's stock were exchanged, compared to its average volume of 2,334,847. The firm's 50 day simple moving average is $2.07 and its two-hundred day simple moving average is $3.51. The company has a debt-to-equity ratio of 0.89, a current ratio of 10.74 and a quick ratio of 9.94. The stock has a market cap of $542.43 million, a price-to-earnings ratio of -1.30 and a beta of 0.25. Maravai LifeSciences has a fifty-two week low of $1.67 and a fifty-two week high of $10.03.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.01). The firm had revenue of $46.85 million for the quarter, compared to analysts' expectations of $44.01 million. Maravai LifeSciences had a negative net margin of 81.13% and a negative return on equity of 6.61%. The business's revenue for the quarter was down 26.9% on a year-over-year basis. As a group, sell-side analysts forecast that Maravai LifeSciences will post -0.24 EPS for the current fiscal year.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.